ADC2317

ADC2317 is an antibody-drug conjugate (ADC) developed by Hangzhou Adcoris Biopharmacy. As an ADC, it consists of a monoclonal antibody linked to a cytotoxic payload via a chemical linker. The mechanism of action for ADCs generally involves the selective targeting of cancer cells through the antibody component, which binds to specific antigens on tumor cells. Upon binding and internalization, the cytotoxic drug is released inside the cell, leading to cell death—typically by disrupting DNA or microtubule function[1][6][8]. Specific details about the target antigen or payload for ADC2317 are not publicly disclosed as of November 2024[1].